{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T03:39:29Z","timestamp":1785469169742,"version":"3.56.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Sanofi-Aventis France"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s40264-022-01234-8","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T14:02:44Z","timestamp":1666792964000},"page":"121-128","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Compliance with Prescribing and Dispensing Conditions for Valproate and Related Substances in Girls and Women of Childbearing Potential: A Survey of Community Pharmacists in France"],"prefix":"10.1007","volume":"46","author":[{"given":"Khristina","family":"Fauvelle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8018-6279","authenticated-orcid":false,"given":"Jean Joel","family":"Bigna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,26]]},"reference":[{"key":"1234_CR1","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1042\/BST0371126","volume":"37","author":"N Terbach","year":"2009","unstructured":"Terbach N, Williams RSB. Structure-function studies for the panacea, valproic acid. Biochem Soc Trans. 2009;37:1126\u201332.","journal-title":"Biochem Soc Trans"},{"key":"1234_CR2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1124\/pr.111.005512","volume":"65","author":"C-T Chiu","year":"2013","unstructured":"Chiu C-T, Wang Z, Hunsberger JG, Chuang D-M. Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol Rev. 2013;65:105\u201342.","journal-title":"Pharmacol Rev"},{"key":"1234_CR3","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2165\/00023210-200216100-00004","volume":"16","author":"E Perucca","year":"2002","unstructured":"Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs. 2002;16:695\u2013714.","journal-title":"CNS Drugs"},{"key":"1234_CR4","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S0140-6736(82)90908-4","volume":"2","author":"E Robert","year":"1982","unstructured":"Robert E, Guibaud P. Maternal valproic acid and congenital neural tube defects. Lancet. 1982;2:937.","journal-title":"Lancet"},{"key":"1234_CR5","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/S1474-4422(15)00314-2","volume":"15","author":"T Tomson","year":"2016","unstructured":"Tomson T, Battino D, Perucca E. Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug. Lancet Neurol. 2016;15:210\u20138.","journal-title":"Lancet Neurol"},{"key":"1234_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eplepsyres.2008.04.022","volume":"81","author":"K Meador","year":"2008","unstructured":"Meador K, Reynolds MW, Crean S, Fahrbach K, Probst C. Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res. 2008;81:1\u201313.","journal-title":"Epilepsy Res"},{"key":"1234_CR7","first-page":"CD010224","volume":"11","author":"J Weston","year":"2016","unstructured":"Weston J, Bromley R, Jackson CF, Adab N, Clayton-Smith J, Greenhalgh J, et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database Syst Rev. 2016;11:CD010224.","journal-title":"Cochrane Database Syst Rev"},{"key":"1234_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-017248","volume":"7","author":"AA Veroniki","year":"2017","unstructured":"Veroniki AA, Rios P, Cogo E, Straus SE, Finkelstein Y, Kealey R, et al. Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis. BMJ Open. 2017;7: e017248.","journal-title":"BMJ Open"},{"key":"1234_CR9","doi-asserted-by":"publisher","first-page":"17362","DOI":"10.1038\/s41598-020-74409-x","volume":"10","author":"J Coste","year":"2020","unstructured":"Coste J, Blotiere P-O, Miranda S, Mikaeloff Y, Peyre H, Ramus F, et al. Risk of early neurodevelopmental disorders associated with in utero exposure to valproate and other antiepileptic drugs: a nationwide cohort study in France. Sci Rep. 2020;10:17362.","journal-title":"Sci Rep"},{"key":"1234_CR10","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.yebeh.2008.01.010","volume":"13","author":"SV Thomas","year":"2008","unstructured":"Thomas SV, Ajaykumar B, Sindhu K, Nair MKC, George B, Sarma PS. Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy Behav. 2008;13:229\u201336.","journal-title":"Epilepsy Behav"},{"key":"1234_CR11","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa0803531","volume":"360","author":"KJ Meador","year":"2009","unstructured":"Meador KJ, Baker GA, Browning N, Clayton-Smith J, Combs-Cantrell DT, Cohen M, et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med. 2009;360:1597\u2013605.","journal-title":"N Engl J Med"},{"key":"1234_CR12","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1136\/adc.2009.176990","volume":"96","author":"C Cummings","year":"2011","unstructured":"Cummings C, Stewart M, Stevenson M, Morrow J, Nelson J. Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Arch Dis Child. 2011;96:643\u20137.","journal-title":"Arch Dis Child"},{"key":"1234_CR13","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1111\/j.1528-1167.2010.02668.x","volume":"51","author":"RL Bromley","year":"2010","unstructured":"Bromley RL, Mawer G, Love J, Kelly J, Purdy L, McEwan L, et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia. 2010;51:2058\u201365.","journal-title":"Epilepsia"},{"key":"1234_CR14","unstructured":"Agence Europ\u00e9enne du M\u00e9dicament. Le CMD(h) accepte de renforcer les mises en garde concernant l\u2019utilisation de m\u00e9dicaments \u00e0 base de valproate chez les femmes et les filles. Communiqu\u00e9 de presse du 21 novembre 2014. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/referral\/valproate-related-substances-article-31-referral-cmdh-agrees-strengthen-warnings-use-valproate_fr.pdf. Accessed 22 Jan 2020."},{"key":"1234_CR15","unstructured":"Agence Europ\u00e9enne du M\u00e9dicament. Approbation de nouvelles mesures visant \u00e0 pr\u00e9venir l\u2019exposition au valproate pendant la grossesse. Communiqu\u00e9 de presse du 31 mai 2018. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/referral\/valproate-article-31-referral-new-measures-avoid-valproate-exposure-pregnancy-endorsed_fr.pdf. Accessed 22 Jan 2020."},{"key":"1234_CR16","unstructured":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9. Communiqu\u00e9 de presse du 12 juin 2018. Available from: https:\/\/ansm.sante.fr\/actualites\/le-valproate-est-interdit-pendant-la-grossesse-et-ne-doit-plus-etre-prescrit-aux-filles-adolescentes-et-femmes-en-age-de-procreer-sauf-circonstances-exceptionnelles-communique. Accessed 8 June 2021."},{"key":"1234_CR17","unstructured":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9. Valproate: guide \u00e0 destinatation des professionels de sant\u00e9 (version 3, Sept 2018). Saint-Denis, France. 2018."},{"key":"1234_CR18","unstructured":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9. Evaluation aupr\u00e8s des pharmaciens d\u2019officine des mesures de minimisation du risque consistant en des nouvelles conditions de prescription et de d\u00e9livrance (CPD) du valproate. Enqu\u00eate r\u00e9alis\u00e9e par Sanofi Aventis France (Avril-Juillet 2017). 2017. Available from: https:\/\/archiveansm.integra.fr\/var\/ansm_site\/storage\/original\/application\/cfc9902b616321c0fc3bc742dc57053b.pdf. Accessed 8 Jun 2021."},{"key":"1234_CR19","unstructured":"Association des Epid\u00e9miologistes de Langue Fran\u00e7aise. Recommandations de d\u00e9ontologie et bonnes pratiques en \u00e9pid\u00e9miologie. Bordeaux, France. 2007."},{"key":"1234_CR20","unstructured":"Soci\u00e9t\u00e9 fran\u00e7aise de neurologie. Recommandations de bonne pratique: prise en charge d\u2019une premi\u00e8re crise d\u2019\u00e9pilepsie chez l\u2019adulte. Paris, France. 2014."},{"key":"1234_CR21","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/ane.13211","volume":"141","author":"L Harris","year":"2020","unstructured":"Harris L, Lowes O, Angus-Leppan H. Treatment decisions in women of childbearing age on valproate. Acta Neurol Scand. 2020;141:287\u201393.","journal-title":"Acta Neurol Scand"},{"key":"1234_CR22","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/ane.13231","volume":"141","author":"H Angus-Leppan","year":"2020","unstructured":"Angus-Leppan H, Moghim MM, Cock H, Kinton L, Synnott Wells M, Shankar R. Valproate risk form: surveying 215 clinicians involving 4775 encounters. Acta Neurol Scand. 2020;141:483\u201390.","journal-title":"Acta Neurol Scand"},{"key":"1234_CR23","unstructured":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9. Valproate et d\u00e9riv\u00e9s: l\u2019exposition des femmes enceintes a fortement diminu\u00e9 mais persiste: point d\u2019information. Available from: https:\/\/www.ansm.sante.fr\/S-informer\/Points-d-information-Points-d-information\/Valproate-et-derives-l-exposition-des-femmes-enceintes-a-fortement-diminue-mais-persiste-Point-d-information. Accessed 21 Feb 2020."}],"updated-by":[{"DOI":"10.1007\/s40264-022-01268-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:00:00Z","timestamp":1671494400000}}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-022-01234-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-022-01234-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-022-01234-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T15:43:24Z","timestamp":1674834204000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-022-01234-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,26]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1234"],"URL":"https:\/\/doi.org\/10.1007\/s40264-022-01234-8","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40264-022-01268-y","asserted-by":"object"}]},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,26]]},"assertion":[{"value":"28 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2022","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40264-022-01268-y","URL":"https:\/\/doi.org\/10.1007\/s40264-022-01268-y","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All four surveys were funded by Sanofi, France.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Khristina Fauvelle and Jean Joel Bigna are employees of Sanofi, France\u00a0and may hold shares and\/or stock options in the company.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain data from any individual. According to the French Public Health code, ethics committee approval or the granting of exemption of ethic committee approval is not a prerequisite for research not involving human subjects.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Data analyzed in this survey were provided by pharmacists and were not collected data from patients. As this study did not include any patient\/person, written patient consent was not required. Verbal consent was requested before including participants in the surveys.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All data generated by the surveys conducted in 2018 and 2020 are provided in full in this article. The datasets generated by the surveys conducted in 2016 and 2017 are available on the ANSM website at: .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Codes generated during the current study are not publicly available but are available from the corresponding author on reasonable request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"KF participated in the conception and design of the study, provided data, contributed to data analysis and interpretation, and reviewed several versions of the manuscript. JJB contributed to the interpretation of the data and reviewed several versions of the manuscript. KF and JJB approved the final version of the manuscript and its submission for publication.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}